TLX
Income statement / Annual
Last year (2025), Telix Pharmaceuticals Ltd.'s total revenue was $1.21 B,
an increase of 53.91% from the previous year.
In 2025, Telix Pharmaceuticals Ltd.'s net income was -$10.69 M.
See Telix Pharmaceuticals Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.21 B |
$783.21 M |
$502.55 M |
$160.10 M |
$7.60 M |
$5.21 M |
$3.49 M |
$195.14 K |
$0.00 |
$0.00 |
| Cost of Revenue |
$565.20 M
|
$273.53 M
|
$188.16 M
|
$65.17 M
|
$38.68 M
|
$2.02 M
|
$15.36 M
|
$0.00
|
$3.79 K
|
$0.00
|
| Gross Profit |
$640.23 M
|
$509.68 M
|
$314.39 M
|
$94.93 M
|
$5.05 M
|
$3.19 M
|
-$11.88 M
|
$195.14 K
|
-$3.79 K
|
$0.00
|
| Gross Profit Ratio |
0.53
|
0.65
|
0.63
|
0.59
|
0.66
|
0.61
|
-3.41
|
1
|
0
|
0
|
| Research and Development Expenses |
$256.82 M
|
$121.03 M
|
$128.84 M
|
$57.86 M
|
$34.14 M
|
$23.09 M
|
$21.16 M
|
$18.69 M
|
$2.98 M
|
$10.00 K
|
| General & Administrative Expenses |
$143.50 M
|
$121.65 M
|
$78.99 M
|
$49.13 M
|
$41.10 M
|
$18.01 M
|
$11.28 M
|
$8.50 M
|
$2.46 M
|
$20.00 K
|
| Selling & Marketing Expenses |
$211.77 M
|
$85.47 M
|
$54.87 M
|
$37.97 M
|
$5.89 M
|
$1.20 M
|
$312.00 K
|
$577.95 K
|
$213.77 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$356.77 M
|
$207.13 M
|
$134.16 M
|
$87.10 M
|
$46.99 M
|
$19.21 M
|
$11.59 M
|
$9.08 M
|
$2.67 M
|
$20.00 K
|
| Other Expenses |
$0.00
|
$99.39 M
|
$270.00 K
|
$41.90 M
|
-$27.82 M
|
-$13.24 M
|
-$4.37 M
|
$79.29 K
|
$874.80 K
|
$0.00
|
| Operating Expenses |
$613.59 M
|
$427.55 M
|
$263.27 M
|
$186.86 M
|
$53.30 M
|
$29.05 M
|
$28.38 M
|
$27.85 M
|
$6.52 M
|
$30.00 K
|
| Cost And Expenses |
$1.18 B
|
$701.08 M
|
$486.71 M
|
$252.03 M
|
$91.98 M
|
$54.47 M
|
$39.51 M
|
$27.85 M
|
$6.52 M
|
$30.00 K
|
| Interest Income |
$8.74 M
|
$10.86 M
|
$671.00 K
|
$1.00 K
|
$0.00
|
$67.00 K
|
$98.00 K
|
$332.75 K
|
$38.98 K
|
$14.00 K
|
| Interest Expense |
$55.06 M
|
$21.46 M
|
$8.94 M
|
$406.00 K
|
$195.68 K
|
$1.18 M
|
$2.41 M
|
$29.02 K
|
$9.40 K
|
$0.00
|
| Depreciation & Amortization |
$32.67 M
|
$5.69 M
|
$6.74 M
|
$5.38 M
|
$5.17 M
|
$4.31 M
|
$4.24 M
|
$6.97 K
|
$3.79 K
|
$30.00 K
|
| EBITDA |
$79.83 M |
$98.23 M |
$22.97 M |
-$92.84 M |
-$70.07 M |
-$44.94 M |
-$24.48 M |
-$27.64 M |
-$6.77 M |
-$14.00 K |
| EBITDA Ratio |
0.07
|
0.13
|
0.05
|
-0.58
|
-9.22
|
-8.62
|
-7.02
|
-141.64
|
0
|
0
|
| Operating Income Ratio |
0.02
|
0.1
|
0.03
|
-0.57
|
-10.7
|
-8.48
|
-10.34
|
-150.16
|
0
|
0
|
| Total Other Income/Expenses Net |
-$34.54 M
|
-$26.07 M
|
-$12.75 M
|
-$6.69 M
|
-$17.79 M
|
-$11.00 M
|
$4.90 M
|
$11.94 M
|
$142.22 K
|
-$14.00 K
|
| Income Before Tax |
-$7.90 M
|
$56.06 M
|
$3.09 M
|
-$98.62 M
|
-$99.04 M
|
-$60.25 M
|
-$31.12 M
|
-$15.71 M
|
-$6.38 M
|
-$44.00 K
|
| Income Before Tax Ratio |
-0.01
|
0.07
|
0.01
|
-0.62
|
-13.04
|
-11.56
|
-8.93
|
-80.53
|
0
|
0
|
| Income Tax Expense |
$2.79 M
|
$6.14 M
|
-$2.07 M
|
$5.46 M
|
-$18.53 M
|
-$15.37 M
|
-$3.26 M
|
-$1.88 M
|
$0.00
|
$0.00
|
| Net Income |
-$10.69 M
|
$49.92 M
|
$5.21 M
|
-$104.08 M
|
-$80.51 M
|
-$44.89 M
|
-$27.87 M
|
-$13.83 M
|
-$6.38 M
|
-$44.00 K
|
| Net Income Ratio |
-0.01
|
0.06
|
0.01
|
-0.65
|
-10.6
|
-8.61
|
-8
|
-70.87
|
0
|
0
|
| EPS |
-0.0316 |
0.15 |
0.0163 |
-0.34 |
-0.29 |
-0.17 |
-0.12 |
-0.0684 |
-0.0498 |
-0.0003 |
| EPS Diluted |
-0.0316 |
0.14 |
0.0161 |
-0.34 |
-0.29 |
-0.17 |
-0.12 |
-0.0684 |
-0.0498 |
-0.0003 |
| Weighted Average Shares Out |
$337.88 M
|
$331.23 M
|
$319.18 M
|
$310.64 M
|
$282.21 M
|
$257.27 M
|
$233.44 M
|
$202.12 M
|
$127.99 M
|
$127.99 M
|
| Weighted Average Shares Out Diluted |
$337.88 M
|
$345.19 M
|
$323.71 M
|
$310.64 M
|
$282.21 M
|
$257.27 M
|
$233.44 M
|
$202.12 M
|
$127.99 M
|
$127.99 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
